GenoSpace awarded NIH grant to enable enhanced data access, cohort construction for biorepositories

NewsGuard 100/100 Score

GenoSpace, a precision medicine software company that has developed a comprehensive suite of tools to enable the broad use of genomic data in research and clinical care, today announced that it has been awarded Phase I of a Fast Track Small Business Innovation Research Grant (SBIR) from the National Institutes of Health (NIH) to enable enhanced data access and cohort construction for biorepositories.

During the past decade, the cost of generating genomic sequence and other biomedical data has fallen precipitously, creating a rapidly growing demand for advanced systems to analyze and interpret those data. GenoSpace provides a unified software platform that addresses the data access, analysis, interpretation, and reporting needs of diverse user groups--including research scientists, pathologists, oncologists, clinical trial specialists, medical directors, and patients. Built on a secure, scalable, flexible and robust technology stack, the GenoSpace system is designed to not only address today's challenges, but to anticipate and meet the challenges of tomorrow.

The Phase I grant will support extension of the GenoSpace for Research™ population analytics platform to support advanced data management and analysis and study design for biomedical research samples stored in the National Institute on Drug Abuse (NIDA) Center for Genetic Studies biobank. The resulting GenoSpace for Biobanks™ platform would provide a framework for expanded access to resources in other biorepositories.

"The NIDA biorepository and others like it are essential resources for investigating the molecular basis of disease," said Mick Correll, CTO and COO of GenoSpace and Principal Investigator of the project. "Maximizing their value requires sophisticated software systems that can provide access to the combined genomic and phenotypic information associated with the banked samples and can enable complex analyses to search for genetic and multi-omic correlations with clinically relevant endpoints. Our tools will provide a platform for more efficient study design and post-study data collection and analysis. We are tremendously excited about this award and the opportunity to adapt our platform to add substantial value to these important resources."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Siblings with unique gene mutation offer insights into type 1 diabetes treatment